Roche snaps up ex-US rights to Sarepta’s DMD gene therapyRoche has bought ex-US rights to Sarepta’s Duchenne muscular dystrophy (DMD) gene therapy in a potential multi-billion dollar Share XRoche snaps up ex-US rights to Sarepta’s DMD gene therapyhttps://pharmaphorum.com/news/roche-snaps-up-ex-us-rights-to-sareptas-dmd-gene-therapy/
Solid Bio hit as FDA slaps clinical hold on DMD gene therapyThe FDA has placed another clinical hold on a gene therapy for Duchenne muscular dystrophy developed by Solid Share XSolid Bio hit as FDA slaps clinical hold on DMD gene therapyhttps://pharmaphorum.com/news/solid-bio-hit-as-fda-slaps-clinical-hold-on-dmd-gene-therapy/
Roche joins others in dropping myostatin inhibitor for DMDThe prospects of a new class of Duchenne muscular dystrophy therapies have taken another downturn after Roche abandoned Share XRoche joins others in dropping myostatin inhibitor for DMDhttps://pharmaphorum.com/news/roche-joins-others-in-dropping-myostatin-inhibitor-for-dmd/
NS Pharma steals a march on Sarepta with DMD drugJapan’s Nippon Shinyaku Pharma has filed for approval of its Duchenne muscular dystrophy (DMD) in the US, increasing Share XNS Pharma steals a march on Sarepta with DMD drughttps://pharmaphorum.com/news/ns-pharma-steals-a-march-on-sarepta-with-dmd-drug/
FDA says no to Sarepta’s golodirsen, blocking bid to expand its Duchenne stableThe FDA has rejected Sarepta Therapeutics’ new Duchenne muscular dystrophy (DMD) Vyondys 53 due to concerns about potential Share XFDA says no to Sarepta’s golodirsen, blocking bid to expand its Duchenne stablehttps://pharmaphorum.com/news/fda-says-no-to-sarepta-blocking-bid-to-expand-its-duchenne-stable/
Sarepta DMD gene therapy could improve patients’ motor functionSarepta Therapeutics announced potentially game-changing results from its Duchenne muscular dystrophy gene therapy candidate, with a small phase Share XSarepta DMD gene therapy could improve patients’ motor functionhttps://pharmaphorum.com/news/sarepta-dmd-gene-therapy-could-improve-patients-motor-function/
Curing DMD: Travelling together to find a meaningful destinationFor many years, Duchenne muscular dystrophy (DMD) was something of a forgotten disease. The boys, and some girls, Share XCuring DMD: Travelling together to find a meaningful destinationhttps://pharmaphorum.com/disease-spotlight/dmd-main/curing-dmd-travelling-together-to-find-a-meaningful-destination/
Increase collaboration to widen access to DMD drugs, trials and careWhen it comes to fighting a rare disease like Duchenne muscular dystrophy (DMD), it’s a matter of strength Share XIncrease collaboration to widen access to DMD drugs, trials and carehttps://pharmaphorum.com/disease-spotlight/increase-collaboration-to-widen-access-to-dmd-drugs-trials-and-care/
Pfizer axes development of Duchenne muscular dystrophy antibodyPfizer has axed trials of its domagrozumab antibody for Duchenne muscular dystrophy (DMD), after it failed against efficacy Share XPfizer axes development of Duchenne muscular dystrophy antibodyhttps://pharmaphorum.com/news/duchenne-trials-axed-pfizer-dmd/
